OncoMatch/Clinical Trials/NCT06725524
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
Is NCT06725524 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies JMT601 for b-cell non hodgkin lymphoma.
Treatment: JMT601 — This is a Phase 1, open-label, multi-center study to evaluate the safety of JMT601 in the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma and to determine the recommended dose for Phase 2 studies (RP2D). Study consists of 2 parts. The first part is a dose-escalation part using a 3+3 design with up to 6 dose(0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 12 mg/kg and 20 mg/kg) escalation cohorts at increasing levels. The second part is a dose-expansion part at R2PD dose to assess preliminary efficacy of JMT601.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20-positive)
CD20-positive B-cell non-Hodgkin lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CD47-targeted therapy
previously received targeted CD47 ... therapy
Cannot have received: SIRPA-targeted therapy
previously received ... signal regulatory protein α (SIRRP α) therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
received allogeneic hematopoietic stem cell transplantation (HSCT)
Cannot have received: organ transplantation
other organ transplantation
Lab requirements
Blood counts
ANC ≥1.0×10^9/L; Platelets ≥75×10^9/L (if bone marrow invasion doesn't exist)/≥50.0×10^9/L (if bone marrow invasion exists); Hemoglobin ≥90 g/L; International Standardized ratio and activated partial thromboplastin time ≤1.5 × ULN
Kidney function
Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min
Liver function
Total bilirubin ≤1.5×ULN, alanine aminotransferase ≤2.5×ULN, aspartate aminotransferase ≤2.5×ULN; Subjects with liver lesion: TBIL≤3×ULN, ALT≤5×ULN, AST≤5×ULN
Suitable organ and hematopoietic function: ... see criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06725524 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD47-targeted therapy, SIRPA-targeted therapy, allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Does this trial require MS4A1?
Yes, MS4A1 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages